In yesterday’s Wall Street session, Pfizer Inc. (NYSE:PFE) shares traded at $37.01, up 0.95% from the previous session.
As of this writing, 27 analysts cover Pfizer Inc. (NYSE:PFE). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $75.00 and a low of $32.00, we find $41.00. Given the previous closing price of $36.66, this indicates a potential upside of 11.84 percent. PFE stock price is now 0.45% away from the 50-day moving average and -12.02% away from the 200-day moving average. The market capitalization of the company currently stands at $208.10B.
There are 15 analysts who have given it a hold rating, whereas 10 have given it a buy rating. Brokers who have rated the stock have averaged $44.09 as their price target over the next twelve months.
With the price target reduced from $45 to $41, JP Morgan maintained Neutral rating for Pfizer Inc. (NYSE: PFE).
In other news, Gottlieb Scott, Director bought 1,000 shares of the company’s stock on May 08. The stock was bought for $38,580 at an average price of $38.58. Upon completion of the transaction, the Director now directly owns 6,000 shares in the company, valued at $0.22 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 05, Director Gottlieb Scott bought 1,000 shares of the business’s stock. A total of $38,425 was incurred on buying the stock at an average price of $38.42. This leaves the insider owning 5,000 shares of the company worth $0.19 million. Insiders disposed of 545,539 shares of company stock worth roughly $20.19 million over the past 1 year. A total of 0.04% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PFE stock. A new stake in Pfizer Inc. shares was purchased by AUSTRALIANSUPER PTY LTD during the first quarter worth $99,891,000. MN SERVICES VERMOGENSBEHEER B.V. invested $99,805,000 in shares of PFE during the first quarter. In the first quarter, PORTSIDE WEALTH GROUP, LLC acquired a new stake in Pfizer Inc. valued at approximately $86,001,000. ARMISTICE CAPITAL, LLC acquired a new stake in PFE for approximately $77,573,000. UNISUPER MANAGEMENT PTY LTD purchased a new stake in PFE valued at around $57,468,000 in the second quarter. In total, there are 3,882 active investors with 70.50% ownership of the company’s stock.
Monday morning saw Pfizer Inc. (NYSE: PFE) opened at $36.71. During the past 12 months, Pfizer Inc. has had a low of $34.65 and a high of $54.93. As of last week, the company has a debt-to-equity ratio of 0.66, a current ratio of 2.10, and a quick ratio of 1.80. The fifty day moving average price for PFE is $36.85 and a two-hundred day moving average price translates $42.07 for the stock.
The latest earnings results from Pfizer Inc. (NYSE: PFE) was released for Jul, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $0.62, beating analysts’ expectations of $0.52 by 0.1. This compares to $0.01 EPS in the same period last year. The net profit margin was 27.50% and return on equity was 22.10% for PFE. The company reported revenue of $12.73 billion for the quarter, compared to $27.74 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -54.1 percent. For the current quarter, analysts expect PFE to generate $13.52B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 09/05/2023. Investors who held shares on 07/28/2023 were paid a $0.41 dividend. On an annualized basis, this represents a $1.64 dividend and a 4.43% percent yield. There was an ex-dividend date of 07/27/2023 for this dividend. In terms of dividend payout ratio, PFE is presently at 42.40%.
